title: Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.
abstract: OBJECTIVE
  To describe working status in patients with RA, AS and PsA treated with anti-TNF therapy registered with the British Society for Rheumatology Biologics Register.
  
  
  METHODS
  Patients with RA (n = 3291), AS (n = 229) and PsA (n = 254) treated with anti-TNF therapy were included in this study. In addition, biologic-naive patients with RA (n = 379) were included. At baseline and 3 years after registration, all patients reported their working status. Baseline characteristics between working and work-disabled patients were compared. Logistic regression analysis was applied to identify factors associated with new work disability in patients with RA.
  
  
  RESULTS
  At baseline, work disability rates were already high: 49% for RA, 39% for PsA, 41% for AS and 36% for biologic-naive patients. Work-disabled patients had a higher HAQ score and worse disease activity than working patients. Working patients with a high HAQ score [odds ratio (OR) 2.79; 95% CI 1.89, 4.12] and a manual job (OR 2.31; 95% CI 1.52, 3.52) at baseline were more likely to become work disabled at follow-up, while those patients in remission 6 months after commencing anti-TNF therapy were less likely to become work disabled. However, use of anti-TNF therapy did not prevent patients with RA from becoming work disabled (OR for RA control patients vs RA anti-TNF patients 0.80; 95% CI 0.36, 1.81, adjusted for baseline variables).
  
  
  CONCLUSIONS
  A high percentage of patients with RA, AS and PsA were already work disabled at the start of anti-TNF therapy. There is less future work disability in working patients with RA who responded to anti-TNF therapy.
authors.affiliation: ARC Epidemiology Unit, University of Manchester, Stopford Building, Oxford Road, Manchester M13 9PT, UK.
authors.forename: Suzanne M M
authors.initials: SM
authors.lastname: Verstappen
authors.forename: Kath D
authors.initials: KD
authors.lastname: Watson
authors.forename: Mark
authors.initials: M
authors.lastname: Lunt
authors.forename: Katie
authors.initials: K
authors.lastname: McGrother
authors.forename: Deborah P M
authors.initials: DP
authors.lastname: Symmons
authors.forename: Kimme L
authors.initials: KL
authors.lastname: Hyrich
mesh_terms: D000293:Adolescent; D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D006233:Persons with Disabilities / Q000534:rehabilitation*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012042:Registries; D012720:Severity of Illness Index; D025242:Spondylarthropathies / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006113:United Kingdom; D014937:Work; D014938:Work Capacity Evaluation; D055815:Young Adult
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha
references.citation: Arthritis Rheum. 2008 Aug 15;59(8):1082-9
references.pmid: 18668597
references.citation: Ann Rheum Dis. 2005 Aug;64(8):1150-7
references.pmid: 15677701
references.citation: Arthritis Rheum. 2008 Oct 15;59(10):1467-74
references.pmid: 18821658
references.citation: Arthritis Rheum. 2008 Apr 15;59(4):510-4
references.pmid: 18383415
references.citation: Stat Med. 1999 Mar 30;18(6):681-94
references.pmid: 10204197
references.citation: Arthritis Rheum. 2006 Feb;54(2):678-81
references.pmid: 16447247
references.citation: Arthritis Rheum. 2003 Nov;48(11):3046-54
references.pmid: 14613265
references.citation: Ann Rheum Dis. 2004 Mar;63(3):221-5
references.pmid: 14962951
references.citation: J Rheumatol. 2007 Nov;34(11):2211-7
references.pmid: 17787043
references.citation: Arthritis Rheum. 1998 Oct;41(10):1845-50
references.pmid: 9778226
references.citation: Arthritis Rheum. 2006 Aug 15;55(4):569-74
references.pmid: 16874778
references.citation: Lancet. 2004 Feb 28;363(9410):675-81
references.pmid: 15001324
references.citation: Lancet. 1999 Dec 4;354(9194):1932-9
references.pmid: 10622295
references.citation: Arthritis Rheum. 1995 Jan;38(1):44-8
references.pmid: 7818570
references.citation: J Rheumatol. 2004 May;31(5):849-55
references.pmid: 15124242
references.citation: J Rheumatol. 1994 Dec;21(12):2286-91
references.pmid: 7699630
references.citation: Ann Rheum Dis. 2006 Jul;65(7):895-8
references.pmid: 16339291
references.citation: J Rheumatol. 2006 Apr;33(4):665-70
references.pmid: 16568506
references.citation: Ann Rheum Dis. 2006 Apr;65(4):471-7
references.pmid: 16096330
references.citation: Ann Rheum Dis. 2008 Feb;67(2):238-43
references.pmid: 17644550
references.citation: Rheumatology (Oxford). 2008 Apr;47(4):481-3
references.pmid: 18281690
references.citation: Arthritis Rheum. 2004 Jun 15;51(3):488-97
references.pmid: 15188338
references.citation: Arthritis Rheum. 2005 Dec 15;53(6):856-63
references.pmid: 16342093
references.citation: Arthritis Rheum. 2003 Jan;48(1):35-45
references.pmid: 12528101
references.citation: J Rheumatol. 2005 Apr;32(4):721-8
references.pmid: 15801031
references.citation: Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii28-9
references.pmid: 14532144
references.citation: Nat Clin Pract Rheumatol. 2006 Oct;2(10):546-53
references.pmid: 17016480
references.citation: Arthritis Rheum. 2006 Mar;54(3):716-22
references.pmid: 16508932
references.citation: J Rheumatol. 2006 Nov;33(11):2254-9
references.pmid: 16960923
references.citation: Br J Rheumatol. 1986 May;25(2):206-9
references.pmid: 3708236
references.citation: Rheumatology (Oxford). 2005 Feb;44(2):157-63
references.pmid: 15637039